The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Chronic Reductions in Serotonin Transporter Function Prevent 5-HT1B-Induced Behavioral Effects in Mice
Open accessAbstract
Background Obsessive-compulsive disorder (OCD) is characterized by intrusive thoughts, images, or impulses and/or repetitive stereotypical behavior. Obsessive-compulsive disorder patients exhibit reduced prepulse inhibition (PPI) and symptom exacerbation after challenge with 5-HT1B receptor agonists. Recently, gain-of-function alleles of the serotonin transporter (5-HTT) have been associated with OCD. We tested the hypothesis that reducing 5-HTT function chronically, either genetically or via serotonin reuptake inhibitor (SRI) treatment, attenuates PPI deficits and perseverative hyperlocomotion induced by 5-HT1B agonists in mice.Methods Mice received subchronic or chronic pretreatment with the SRI fluoxetine and acute treatment with RU24969 (5-HT1A/1B agonist) or 8-OH-DPAT (5-HT1A agonist) and were assessed for PPI, locomotor activity, and spatial patterns of locomotion. The same measures were evaluated in 5-HTT wild-type (WT), heterozygous (HT), and knockout (KO) mice after RU24969 treatment. The effects of WAY100635 (5-HTA antagonist) or GR127935 (5-HT1B/D antagonist) pretreatment on RU24969-induced effects were evaluated. Finally, 5-HT1B binding and functional coupling were assessed in 5-HTT-WT, -HT, and -KO mice, and normal fluoxetine-treated mice.Results Chronic, but not subchronic, fluoxetine treatment prevented RU24969-induced PPI deficits and perseverative hyperlocomotion. These RU24969-induced effects were mediated via 5-HT1B and not 5-HT1A receptors. 5-HTT-KO mice showed no effects of RU24969, and 5-HTT-HT mice exhibited intermediate phenotypes. 5-HT1B binding and functional coupling were reduced in the globus pallidus and substantia nigra of 5-HTT-KO mice.Conclusions Our results demonstrate that chronic, but not subchronic, fluoxetine treatment and 5-HTT knockout robustly attenuate 5-HT1B agonist-induced PPI deficits and perseverative hyperlocomotion. These results may have implications for the etiology and treatment of OCD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“studies in mice demonstrate that administration of a 5-HT1B agonist leads to OCD-relevant perseverative locomotion and prepulse inhibition deficits, both of which are reversed with chronic, but not acute, fluoxetine treatment 38.”
From DISSECTING OCD CIRCUITS: FROM ANIMAL MODELS TO TARGETED TREATMENTS: Review: Dissecting OCD Circuits: Animals to Treatments (2015) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BRAFF, D. L., Geyer, M. A., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100810 · Cited by 1,701
Self-citationGeyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484
Self-citationHu, X.-Z., Lipsky, R., Zhu, G., Akhtar, L. A., Taubman, J., Greenberg, B., Xu, K., Arnold, P., Richter, M., Kennedy, J., et al. (2006) · American Journal of Human Genetics · doi:10.1086/503850 · Cited by 1,215
The more or less startling effects of weak prestimulation
Graham, F. K. (1975) · Psychophysiology · doi:10.1111/j.1469-8986.1975.tb01284.x · Cited by 1,119
Neuropsychopharmacology: The Fifth Generation of Progress
Sagduyu, K. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.7.1251-a · Cited by 1,023
Enhanced Aggressive Behavior in Mice Lacking 5-HT 1B Receptor
Saudou, F., Amara, D. A., Dierich, A., LeMeur, M., Ramboz, S., Ségu, L., Buhot, M.-C., & Hen, R. (1994) · Science · doi:10.1126/science.8091214 · Cited by 839
Self-citationNeuropsychopharmacology : The Fifth Generation of Progress
Davis, K. L., Charney, D. S., Coyle, J. T., & Nemeroff, C. B. (2002) · Lippincott Williams & Wilkins eBooks · Cited by 747
Effects of Chronic Fluoxetine in Animal Models of Anxiety and Depression
Dulawa, S. C., Holick, K. A., Gundersen, B., & Hen, R. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300433 · Cited by 671
Self-citationBrain anatomy and sensorimotor gating in Asperger's syndrome
McAlonan, G. M. (2002) · Brain · doi:10.1093/brain/awf150 · Cited by 447
Gordon, C. T. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820180039004 · Cited by 390
Swerdlow, N. R., Caine, S. B., BRAFF, D. L., & Geyer, M. A. (1992) · Journal of Psychopharmacology · doi:10.1177/026988119200600210 · Cited by 388
Self-citationLira, A., Zhou, M., Castanon, N., Ansorge, M. S., Gordon, J. A., Francis, J. H., Bradley-Moore, M., Lira, J., Underwood, M. D., Arango, V., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00696-6 · Cited by 385
Self-citationA preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder
Swerdlow, N. R., Benbow, C. H., Zisook, S., Geyer, M. A., & BRAFF, D. L. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90300-3 · Cited by 351
Self-citationPeroutka, S. J. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb04532.x · Cited by 347
Oksenberg, D., Marsters, S. A., O’Dowd, B. F., Jin, H., Havlik, S., Peroutka, S. J., & Ashkenazi, A. (1992) · Nature · doi:10.1038/360161a0 · Cited by 276
Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype
Ozaki, N., Goldman, D. A., Kaye, W. H., Plotnicov, K. H., Greenberg, B. D., Lappalainen, J., Rudnick, G., & Murphy, D. L. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001365 · Cited by 275
Fabre, V., Beaufour, C., Evrard, A., Bilan, A. R., Hanoun, N., Lesch, K., Murphy, D. L., Lanfumey, L., Hamon, M., & Martres, M. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00126.x · Cited by 274
5-hydroxytryptamine1B receptors block the GABAB synaptic potential in rat dopamine neurons
Johnson, S., Mercuri, N. B., & North, R. (1992) · Journal of Neuroscience · doi:10.1523/jneurosci.12-05-02000.1992 · Cited by 245
Delfs, J. M., & Kelley, A. E. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90221-o · Cited by 200
Impaired Prepulse Inhibition of Acoustic Startle in Obsessive-Compulsive Disorder
Hoenig, K., Hochrein, A., Quednow, B. B., Maier, W., & Wagner, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.040 · Cited by 190
Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release
Guan, X.-M., & McBride, W. J. (1989) · Brain Research Bulletin · doi:10.1016/0361-9230(89)90198-6 · Cited by 187
Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats
Sipes, T. E., & Geyer, M. A. (1994) · Neuropharmacology · doi:10.1016/0028-3908(94)90074-4 · Cited by 184
Self-citationBakshi, V. P., & Geyer, M. A. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-20-08394.1998 · Cited by 167
Self-citationSprouse, J. S., Reynolds, L. S., Li, X., Braselton, J. P., & Schmidt, A. W. (2003) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.08.007 · Cited by 137
A novel, putative gain-of-function haplotype at SLC6A4 associates with obsessive-compulsive disorder
Wendland, J. R., Moya, P. R., Kruse, M. R., Ren‐Patterson, R. F., Jensen, C. L., Timpano, K. R., & Murphy, D. L. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm343 · Cited by 136
Dulawa, S. C., Hen, R., Scearce-Levie, K. A., & Geyer, M. A. (1997) · Psychopharmacology · doi:10.1007/s002130050328 · Cited by 122
Self-citationPaulus, M. P., Dulawa, S. C., Ralph, R. J., & Geyer, M. A. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01137-3 · Cited by 117
Self-citationIs the 5-HT1Dβ Receptor Gene Implicated in the Pathogenesis of Obsessive-Compulsive Disorder?
Mundo, E., Richter, M. A., Sam, F., Macciardi, F. M., & Kennedy, J. L. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.7.1160 · Cited by 103
Effects of strain and serotonergic agents on prepulse inhibition and habituation in mice
Dulawa, S. C., & Geyer, M. A. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00030-7 · Cited by 99
Self-citationBakshi, V. P., & Geyer, M. A. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37049-1 · Cited by 99
Self-citationFletcher, P. J., Sinyard, J., & Higgins, G. A. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0453-9 · Cited by 93
Serotonin1B Receptor Activation Mimics Behavioral Effects of Presynaptic Serotonin Release
Rempel, N. L., Callaway, C. W., & Geyer, M. A. (1993) · Neuropsychopharmacology · doi:10.1038/npp.1993.22 · Cited by 91
Self-citationParker, E. M., Grisel, D. A., Iben, L. G., & Shapiro, R. A. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb05865.x · Cited by 91
Gross‐Isseroff, R., Cohen, R., Sasson, Y., Voet, H., & Zohar, J. (2004) · Neuropsychobiology · doi:10.1159/000079970 · Cited by 86
American Academy of Pediatrics. Presidential address--1974.
Gillespie, J. B. (1974) · PubMed · Cited by 75
Stein, D. J., van Heerden, B., Wessels, C., van Kradenburg, J., Warwick, J., & Wasserman, H. J. (1999) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(99)00051-2 · Cited by 74
Pejchal, T., Foley, M., Kosofsky, B. E., & Waeber, C. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704555 · Cited by 72
Self-citationSumatriptan, 5-HT1D receptors and obsessive-compulsive disorder
Koran, L. M., Pallanti, S., & Quercioli, L. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)00082-7 · Cited by 71
Callaway, C. W., & Geyer, M. A. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10342-x · Cited by 64
Self-citationHollander, E. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00121-9 · Cited by 64
Serotonin-1D hypothesis of obsessive-compulsive disorder: an update.
Zohar, J., Kennedy, J. L., Hollander, E., & Koran, L. M. (2004) · PubMed · Cited by 63
Cheetham, S. C., & Heal, D. J. (1993) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1993.tb14010.x · Cited by 61
Quednow, B. B., K�hn, K.-U., Stelzenmueller, R., Hoenig, K., Maier, W., & Wagner, M. (2003) · Psychopharmacology · doi:10.1007/s00213-004-1842-6 · Cited by 53
DNA variation and psychopharmacology of the human serotonin receptor 1B(HTR1B) gene
Sanders, A. R., Duan, J., & Gejman, P. V. (2002) · Pharmacogenomics · doi:10.1517/14622416.3.6.745 · Cited by 52
Oberlander, C., Blaquière, B., & Pujol, J. F. (1986) · Neuroscience Letters · doi:10.1016/0304-3940(86)90382-4 · Cited by 51
Delorme, R., Betancur, C., Wagner, M., Krebs, M., Gorwood, P. A. P. M., Pearl, P. L., Nygren, G., Durand, C. M., Buhtz, F., Pickering, P., et al. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001728 · Cited by 51
Higgins, G. A., JORDAN, C. C., & Skingle, M. (1991) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1991.tb12170.x · Cited by 47
Sumatriptan (5-HT 1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder
Pian, K. L. H., Westenberg, H. G. M., van Megen, H. J. G. M., & den Boer, J. A. (1998) · Psychopharmacology · doi:10.1007/s002130050777 · Cited by 40
Sulpiride injection into the dorsal striatum increases methamphetamine-induced gnawing in rats
Koshikawa, N., Aoki, S., Tomiyama, K., Maruyama, Y., & Kobayashi, M. (1987) · European Journal of Pharmacology · doi:10.1016/0014-2999(87)90213-5 · Cited by 39
Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype
Ozaki, N., Goldman, D. A., Kaye, W. H., Plotnicov, K. H., Greenberg, B. D., Lappalainen, J., Rudnick, G., & Murphy, D. L. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001415 · Cited by 37
Chaouloff, F., Courvoisier, H., Moisan, M., & Mormède, P. (1999) · Psychopharmacology · doi:10.1007/s002130050841 · Cited by 36
Dulawa, S. C., Hen, R., Scearce-Levie, K. A., & Geyer, M. A. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb10176.x · Cited by 33
Self-citationIncreased growth hormone response to sumatriptan challenge in adult autistic disorders
Novotny, S., Hollander, E., Allen, A., Mosovich, S., Aronowitz, B., Cartwright, C., DeCaria, C. M., & Dolgoff-Kaspar, R. (2000) · Psychiatry Research · doi:10.1016/s0165-1781(00)00134-7 · Cited by 29
Paulus, M. P., & Geyer, M. A. (1993) · Psychopharmacology · doi:10.1007/bf02245695 · Cited by 27
Self-citationWisniecki, A., Correa, M., Arizzi, M. N., Ishiwari, K., & Salamone, J. D. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1521-z · Cited by 27
Boshuisen, M. L., & den Boer, J. A. (2000) · Psychopharmacology · doi:10.1007/s002130000529 · Cited by 24
Effects of acute treatment with antidepressant drugs on sensorimotor gating deficits in rats
Pouzet, B., Andersen, M. P., & Hogg, S. L. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1976-6 · Cited by 22
5‐HT3 receptor antagonism by anpirtoline, a mixed 5‐HT1 receptor agonist/5‐HT3 receptor antagonist
Göthert, M., Hamon, M., Barann, M., Bönisch, H., GOZLAN, H., Laguzzi, R. F., Metzenauer, P., Nickel, B., & Szelenyi, I. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb13222.x · Cited by 22
Boulenguez, P., Peters, S. L., Mitchell, S. N., Chauveau, J., Gray, J. A., & Joseph, M. H. (1998) · Journal of Psychopharmacology · doi:10.1177/026988119801200305 · Cited by 21
Cited by
Sorted by citations
Pittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
Haenisch, B., & Bönisch, H. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.12.002 · Cited by 215
Conserved role for the serotonin transporter gene in rat and mouse neurobehavioral endophenotypes
Kalueff, A. V., Olivier, J. D. A., Nonkes, L. J. P., & Homberg, J. R. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.08.003 · Cited by 206
Impaired sensorimotor gating in unmedicated adults with obsessive-compulsive disorder
Ahmari, S. E., Risbrough, V. B., Geyer, M. A., & Simpson, H. B. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.308 · Cited by 189
Self-citationAnimal models of depression and anxiety: What do they tell us about human condition?
Neumann, I. D., Wegener, G., Homberg, J. R., Cohen, H., Slattery, D. A., Zohar, J., Olivier, J. D. A., & Mathé, A. A. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.028 · Cited by 164
Metadata
- Authors
- Shanahan, N. A., Holick Pierz, K. A., Masten, V. L., Waeber, C., Ansorge, M., Gingrich, J. A., Geyer, M. A., Hen, R., & Dulawa, S. C.
- Affiliations
- University of California San Diego (US)
- Harvard University (US)
- Columbia University (US)
- University of Chicago (US)
- Corresponding author
- Dulawa, Stephanie C.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2009-03
- Volume
- 65
- Issue
- 5
- Pages
- 401-408
- ISSN
- 0006-3223 (ISSN-L)
- PMC
- PMC2674010
- OpenAlex
- W2058616430
- Cited by
- 102
- References
- 60
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 13 · 2020: 6 · 2019: 8 · 2018: 3 · 2017: 1 · 2016: 8 · 2015: 5 · 2014: 5 · 2013: 9 · 2012: 8
- FWCI
- 9.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (K01MH071555, R01MH079424)
- National Institute on Drug Abuse (DA 02925, T32DA07255-15, R01DA002925, T32DA007255)
- National Institute of Neurological Disorders and Stroke (R01NS049263, R21NS052195)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- serotonin transporter, 5-HT1B receptor, obsessive-compulsive disorder, prepulse inhibition, fluoxetine, serotonin reuptake inhibitors, 8-OH-DPAT, 5-HT1A receptor, globus pallidus, substantia nigra, gain-of-function alleles
- MeSH terms
- Animals, Female, Fluoxetine, Globus Pallidus, Indoles, Mice, Inbred BALB C, Motor Activity, Oxadiazoles, Piperazines, Pyridines, Reflex, Startle, Substantia Nigra, 8-Hydroxy-2-(di-n-propylamino)tetralin, Mice, Knockout, Receptor, Serotonin, 5-HT1B, Serotonin Plasma Membrane Transport Proteins, Mice, Serotonin 5-HT1 Receptor Agonists, Serotonin 5-HT1 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
